Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that sales for oral topotecan for the treatment of small-cell lung cancer will reach $63 million in 2008 and $103 million in 2013. Although oral topotecan is having an overall positive effect on market growth, it is replacing intravenous(IV) topotecan, one of the major sellers in 2003.

"According to physicians we interviewed, oral topotecan will reap commercial rewards in the second-line setting despite its lack of a significant efficacy improvement over other second-line treatment options, namely IV topotecan," said Mohamed Muhsin, analyst at Decision Resources. "Oral topotecan will fulfill a large clinical unmet need by offering a conveniently administered therapy to those patients who would otherwise opt for best supportive care, either because they reside too far away from the hospital or because they prefer to live their remaining few weeks of life without the burden of hospital-based therapy."

The Challenge for the Small-Cell Lung Cancer Drug Market

Therapy for small-cell lung cancer is characterized by good initial response rates but high relapse rates and poor long-term survival. Prevention of relapse resulting in increased survival remains the greatest area of challenge in this disease.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Decision Resources and PharMetrics Partner to Enhance the Way Pharmaceutical Companies Analyze Their Disease Markets

View Now